Ensign Peak Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.08M | Sell |
315,564
-199,245
| -39% | -$5.73M | 0.02% | 500 |
|
|
2025
Q1 | $17.3M | Buy |
514,809
+12,119
| +2% | +$406K | 0.03% | 330 |
|
|
2024
Q4 | $25.7M | Sell |
502,690
-114,147
| -19% | -$5.84M | 0.05% | 281 |
|
|
2024
Q3 | $31.5M | Buy |
616,837
+610
| +0.1% | +$31.2K | 0.06% | 244 |
|
|
2024
Q2 | $27.6M | Sell |
616,227
-5,280
| -0.8% | -$236K | 0.05% | 256 |
|
|
2024
Q1 | $29.1M | Buy |
621,507
+185,822
| +43% | +$8.7M | 0.05% | 257 |
|
|
2023
Q4 | $15.5M | Buy |
435,685
+51,000
| +13% | +$1.81M | 0.03% | 339 |
|
|
2023
Q3 | $11.4M | Buy |
384,685
+114,416
| +42% | +$3.4M | 0.02% | 357 |
|
|
2023
Q2 | $4.87M | Hold |
270,269
| – | – | 0.01% | 595 |
|
|
2023
Q1 | $4.34M | Hold |
270,269
| – | – | 0.01% | 609 |
|
|
2022
Q4 | $4.95M | Buy |
270,269
+177,945
| +193% | +$3.26M | 0.01% | 559 |
|
|
2022
Q3 | $1.81M | Buy |
92,324
+7,700
| +9% | +$151K | ﹤0.01% | 822 |
|
|
2022
Q2 | $1.58M | Buy |
84,624
+23,663
| +39% | +$441K | ﹤0.01% | 906 |
|
|
2022
Q1 | $1.34M | Buy |
60,961
+26,760
| +78% | +$587K | ﹤0.01% | 1048 |
|
|
2021
Q4 | $971K | Buy |
34,201
+13,080
| +62% | +$371K | ﹤0.01% | 1304 |
|
|
2021
Q3 | $445K | Buy |
+21,121
| New | +$445K | ﹤0.01% | 1645 |
|
|
2020
Q2 | – | Sell |
-1,104
| Closed | -$16K | – | 1680 |
|
|
2020
Q1 | $16K | Sell |
1,104
-1,104
| -50% | -$16K | ﹤0.01% | 1619 |
|
|
2019
Q4 | $55K | Buy |
+2,208
| New | +$55K | ﹤0.01% | 1651 |
|